C-UGBRmitochondria transplantation, gene therapy, cellular energy metabolism
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Explore therapeutic mitochondria transfer for rejuvenation or aging-related mitochondria recovery.
Application of the Therapeutic Mitochondria Transplantation platform to aging-related mitochondrial dysfunction.
Seed-round public record says funding would advance the pipeline including a first application in rejuvenation and broadly pursue a first application in aging.
Reduce ischemia-reperfusion injury and delayed graft function in kidney transplantation.
Therapeutic mitochondria transplantation applied as a medicine for ischemia-reperfusion injury, with kidney transplantation as the first indication.
Public record states the kidney-transplantation indication received FDA Orphan Drug Designation and that there is an ongoing clinical pilot at Boston Children's Hospital.
Develop mitochondria transplantation medicines targeting cellular energy metabolism and mitochondria-linked disease processes, with applications including ischemia-reperfusion injury and aging-related mitochondria recovery.
Therapeutic transfer/transplantation of mitochondria to restore or improve cellular energy metabolism.
Seed financing reported to advance the product pipeline; public material describes more than 20 preclinical studies and an ongoing clinical pilot supporting the technology.
Treat Epidermolysis Bullosa by restoring Type VII Collagen expression.
Topical mitochondria-enabled gene therapy targeting COL7A1 / Type VII Collagen expression.
Company site analysis states the program is in development.